|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 74 Windy Hollow Court |
Address2 |
|
| City | Great Falls |
State | VA |
Zip Code | 22066 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401108536-60141
|
||||||||
|
6. House ID# 565120001
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kathleen Jaeger |
Date | 3/5/2025 1:43:23 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office, U.S. Trade Representative (USTR), State - Dept of (DOS), Commerce - Dept of (DOC), Federal Trade Commission (FTC), Office of Management & Budget (OMB), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The Indian Pharmaceutical Alliance (IPA) members play a critical role in the U.S. healthcare system, supplying nearly 50% of Medicare prescriptions. In the top 10 U.S. therapeutic categories, IPA companies provide more than half of the prescriptions for 5 of these categories, with involvement in some categories up to 60%. These statistics underscore the significant impact IPA has on making essential medications accessible and affordable.
Building on this foundation, IPA seeks to enhance U.S.-India supply chain resiliency through strategic partnerships. This initiative aims to secure a reliable and robust supply chain that supports both nations' healthcare systems amidst global uncertainties. Additionally, IPA is dedicated to advancing sustainable reform measures to ensure the long-term affordability and availability of medicine. By advocating for these critical areas, IPA reinforces its commitment to improving healthcare outcomes and industry sustainability, ultimately benefiting patients in both the U.S. and globally.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Natl Security Council (NSC), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The Indian Pharmaceutical Alliance (IPA) is a trade association representing leading global manufacturers of innovative and affordable medicine. In lights of the current global supply chain vulnerabilities, particularly the dependence on China for the majority of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), IPA is actively seeking to forge a U.S.-India affordable medicine supply chain resiliency partnership.
Such a strategic initiative aims to address national security concerns and reduce dependency on a single source for critical generic pharmaceutical components. By enhancing U.S.-India collaboration, IPA aims to establish a more diversified and secure supply chain that supports the steady and reliable production of affordable medicines. This partnership not only promises to bolster national security of both nations but also ensures that they are better prepared to handle health crises by ensuring access to everyday medications.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
The Indian Pharmaceutical Alliance (IPA) actively supports targeted reforms in the U.S. healthcare system to ensure the sustainability of the generic drug industry. IPA advocates for meaningful reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to secure transparent pricing and equitable market practices that directly benefit consumers. Moreover, IPA champions efforts to close loopholes in the Hatch-Waxman Act that impede timely generic drug market entry from remving patent thickets to generic first policies. These strategic initiatives are crucial for maintaining industry sustainability, reducing U.S. healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs commitment to these reforms underscores its dedication to fostering a robust and enduring U.S.generic drug sector.
17. House(s) of Congress and Federal agencies Check if None
White House Office, Health & Human Services - Dept of (HHS), Federal Trade Commission (FTC), Centers For Medicare and Medicaid Services (CMS), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market, upholding the principles of the Hatch-Waxman Act to balance innovation with access. As a significant provider, supplying about 50% of the generic medicines in the American healthcare system, IPA champions policies that allow consumers timely access to affordable medications. This commitment not only supports public health by making essential treatments more accessible but also sustains the healthcare system economically. IPA's efforts in the U.S. underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |